论文部分内容阅读
目的研究子宫内膜癌组织内端粒蛋白TRF1、TRF2的表达水平及临床应用意义。方法选取韶关市第一人民医院2015年1月-2016年12月住院部收治的60例子宫内膜癌患者作为病例组,同时选取同期在我院行诊断性刮宫术治疗的30例健康子宫内膜患者作为对照组。采用免疫组化方法对两组患者的端粒蛋白TRF1、TRF2及细胞分化水平进行检测,并比较两组患者端粒蛋白TRF1、TRF2阳性率。结果子宫内膜癌的病理分级、临床分期、淋巴结转移、肌层浸润等情况与端粒蛋白TRF1、TRF2的表达水平无明显相关性;TRF1、TRF2在子宫内膜癌、健康子宫内膜内表达相关性明显(Rs_1=0.519,P_1=0.000;Rs_2=0.541,P_2=0.000)。结论临床医学可根据端粒蛋白TRF1、TRF2表达水平进行早期子宫内膜癌防治,为临床医学研究提供分子生物学机制,降低子宫内膜癌发生风险,改善治疗效果。
Objective To study the expression of telomerase TRF1 and TRF2 in endometrial carcinoma and its clinical significance. Methods Sixty patients with endometrial cancer who were admitted to First People’s Hospital of Shaoguan City from January 2015 to December 2016 were enrolled as the case group and 30 healthy uterus patients who underwent diagnostic curettage in our hospital at the same time Membrane patients as a control group. The expression of TRF1, TRF2 and cell differentiation were detected by immunohistochemistry in both groups. The positive rates of TRF1 and TRF2 were compared between the two groups. Results The pathological grade, clinical stage, lymph node metastasis and myometrial invasion of endometrial carcinoma had no significant correlation with the expression levels of TRF1 and TRF2. The expressions of TRF1 and TRF2 in endometrial carcinoma and healthy endometrium The correlation was significant (Rs_1 = 0.519, P_1 = 0.000; Rs_2 = 0.541, P_2 = 0.000). Conclusion Clinical medicine can prevent and cure early endometrial cancer according to the expression of telomere protein TRF1 and TRF2, provide molecular biological mechanism for clinical research, reduce the risk of endometrial cancer and improve the therapeutic effect.